AddLife Development AB’s Acquisition Of EuroClone S.p.A.


Nctm Studio Legale and Gianni, Origoni, Grippo, Cappelli & Partners advised on the transaction.

AddLife Development AB signed an agreement to acquire all shares in the Italian company EuroClone S.p.A., which will be included in the Labtech business area.

EuroClone is headquartered in Milan and engages in sales through its own sales resources, as well as through regional agents. The company currently has 58 employees and sales of EUR 27 million in the Italian market. The company’s end customers are primarily hospital laboratories, research centres, private clinics and industrial centres in Italy.

The acquisition represents AddLife’s entry into the Italian market in a segment in which the company is already an established supplier in the Nordic market. AddLife already conducts business in Italy in the Medtech business area.

The deal will close in January 2020. The acquisition is expected to have a marginally positive effect on AddLife’s earnings per share in the 2020 financial year.

Nctm Studio Legale advised AddLife Development AB with a team led by Vittorio Noseda (Picture),assisted by Giuliana Capillo and Isabella Antolini.

Gianni, Origoni, Grippo, Cappelli & Partners advised the shareholders of EuroClone with a team led by Gerardo Carbonelli, alongside Bruno Edoardo Marseglia.

Involved fees earner: Gerardo Carbonelli – Gianni Origoni Grippo Cappelli & Partners; Bruno Edoardo Marseglia – Gianni Origoni Grippo Cappelli & Partners; Isabella Antolini – NCTM; Giuliana Capillo – NCTM; Vittorio Noseda – NCTM;

Law Firms: Gianni Origoni Grippo Cappelli & Partners; NCTM;

Clients: AddLife AB (publ); EuroClone S.p.A.;